{ "run": { "id": "cmnr1479l04c4p65844lu8566", "region": "US", "assetId": "cmnr1479904c0p658uf5itktz", "ticker": "HUM", "snapshotId": "cmnr1479e04c2p658l9393dbi", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:06.247Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr1479e04c2p658l9393dbi", "assetId": "cmnr1479904c0p658uf5itktz", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 198.39, "dayLow": 195.735, "volume": 1593121, "dayHigh": 201.47, "currency": "USD", "prevClose": 197.15, "week52Low": 163.11, "week52High": 315.35 }, "fundamentals": { "pe": 25.9503546099291, "beta": 0.413317572943374, "epsTTM": 9.87, "fcfTTM": 1171000000, "growth": { "epsYoy": -0.01398601398601404, "revenueYoy": 0.1010776063382614 }, "sector": "Hospital & Medical Service Plans", "margins": { "net": 0.009162142152023692, "gross": null, "operating": 0.02085389930898322 }, "website": "https://www.humana.com/", "industry": "Managed healthcare", "pegRatio": -18.5545035460992, "ebitdaTTM": 1870000000, "forwardPe": 28.2704194260486, "marketCap": 29182689695, "totalCash": 4200000000, "totalDebt": 12369000000, "debtEquity": 0.700515376337996, "quickRatio": 1.417655695583017, "revenueTTM": 129664000000, "companyName": "HUMANA INC", "priceToBook": 1.73940818740486, "currentRatio": 2.00250825890126, "dividendYield": 0.0139375609495618, "returnOnAssets": 0.02429000797399252, "returnOnEquity": 0.0672820977515999, "analystOpinions": null, "businessSummary": "Humana Inc. is an American for-profit health insurance company based in Louisville, Kentucky. In 2024, the company ranked 92 on the Fortune 500 list, which made it the highest ranked (by revenues) company based in Kentucky. It is the fourth largest health insurance provider in the U.S.", "enterpriseValue": 39020883020, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 65680, "sharesOutstanding": 120595967, "enterpriseToEbitda": 20.86678236363636, "analystTargetMedian": null, "enterpriseToRevenue": 0.3009384487598717, "operatingCashflowTTM": 921000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:06.242Z" }, "results": [ { "id": "cmnr1479s04c6p658b55lti8z", "runId": "cmnr1479l04c4p65844lu8566", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"HUM\",\"currency\":\"USD\",\"current_price\":198.39,\"target_price_6m\":192,\"target_price_12m\":208,\"recommendation\":\"HOLD\",\"confidence\":0.52,\"thesis_bullets\":[\"Medicare Advantage margin pressure persists with elevated medical loss ratios\",\"Revenue growth of 10% YoY is solid but earnings declining\",\"Forward PE of 28.3x implies further EPS compression ahead\",\"Stock down 37% from 52-week high already pricing in significant headwinds\",\"Thin operating margins of 2.1% leave little room for execution error\"],\"key_drivers\":[{\"driver\":\"Medicare Advantage medical loss ratio trends\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"CMS Star Ratings recovery trajectory\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Medicare Advantage membership growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"CMS reimbursement rate changes\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Cost management and SG&A efficiency\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"V28 risk-adjustment model transition headwind\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Individual MA plan margin normalization\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Revenue diversification into CenterWell/primary care\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Sustained MLR deterioration above 90% compresses margins further\",\"Star ratings decline reduces bonus payments and competitiveness\",\"Regulatory changes to Medicare Advantage reduce industry profitability\",\"Debt load of $12.4B limits financial flexibility during downturn\",\"Forward EPS decline could be steeper than consensus expects\",\"Competitive pressure from UNH, CVS, and new MA entrants\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.03,\"wacc\":0.09,\"terminal_multiple\":12},\"scenarios\":{\"bear\":{\"target_price\":150,\"prob\":0.25,\"notes\":\"MLR stays elevated, star ratings drop further, EPS falls to ~$6 with multiple compression to 16x.\"},\"base\":{\"target_price\":208,\"prob\":0.50,\"notes\":\"Gradual MLR stabilization, EPS ~$7.5-8, market assigns ~26x forward P/E on recovery hope.\"},\"bull\":{\"target_price\":265,\"prob\":0.25,\"notes\":\"Margin recovery exceeds expectations, star ratings rebound, EPS recovers to $10+ with 25x multiple.\"}},\"method_notes\":\"Earnings-power valuation anchored on forward EPS and normalized P/E for managed care. Current forward PE of 28.3x implies ~$7 fwd EPS, significant decline from $9.87 TTM. Base case assumes gradual stabilization, not full recovery. HOLD reflects mixed signals: solid revenue growth offset by margin compression, high uncertainty on MLR trajectory, and stock already discounting significant headwinds. Weighted scenario EV ≈ $208. Disclaimer: not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained MLR deterioration above 90% compresses margins further", "Star ratings decline reduces bonus payments and competitiveness", "Regulatory changes to Medicare Advantage reduce industry profitability", "Debt load of $12.4B limits financial flexibility during downturn", "Forward EPS decline could be steeper than consensus expects", "Competitive pressure from UNH, CVS, and new MA entrants" ], "ticker": "HUM", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual MLR stabilization, EPS ~$7.5-8, market assigns ~26x forward P/E on recovery hope.", "target_price": 208 }, "bear": { "prob": 0.25, "notes": "MLR stays elevated, star ratings drop further, EPS falls to ~$6 with multiple compression to 16x.", "target_price": 150 }, "bull": { "prob": 0.25, "notes": "Margin recovery exceeds expectations, star ratings rebound, EPS recovers to $10+ with 25x multiple.", "target_price": 265 } }, "confidence": 0.52, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.05, "terminal_multiple": 12, "ebit_margin_target": 0.03 }, "key_drivers": [ { "driver": "Medicare Advantage medical loss ratio trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "CMS Star Ratings recovery trajectory", "impact": "HIGH", "direction": "NEG" }, { "driver": "Medicare Advantage membership growth", "impact": "HIGH", "direction": "POS" }, { "driver": "CMS reimbursement rate changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cost management and SG&A efficiency", "impact": "MED", "direction": "POS" }, { "driver": "V28 risk-adjustment model transition headwind", "impact": "MED", "direction": "NEG" }, { "driver": "Individual MA plan margin normalization", "impact": "MED", "direction": "NEG" }, { "driver": "Revenue diversification into CenterWell/primary care", "impact": "MED", "direction": "POS" } ], "method_notes": "Earnings-power valuation anchored on forward EPS and normalized P/E for managed care. Current forward PE of 28.3x implies ~$7 fwd EPS, significant decline from $9.87 TTM. Base case assumes gradual stabilization, not full recovery. HOLD reflects mixed signals: solid revenue growth offset by margin compression, high uncertainty on MLR trajectory, and stock already discounting significant headwinds. Weighted scenario EV ≈ $208. Disclaimer: not investment advice.", "current_price": 198.39, "recommendation": "HOLD", "thesis_bullets": [ "Medicare Advantage margin pressure persists with elevated medical loss ratios", "Revenue growth of 10% YoY is solid but earnings declining", "Forward PE of 28.3x implies further EPS compression ahead", "Stock down 37% from 52-week high already pricing in significant headwinds", "Thin operating margins of 2.1% leave little room for execution error" ], "target_price_6m": 192, "target_price_12m": 208 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 50433, "createdAt": "2026-04-09T05:21:06.247Z", "usage": { "inputTokens": 3580, "outputTokens": 2317, "costUsd": 0.075825 } }, { "id": "cmnr1479s04c9p658tm25ejnh", "runId": "cmnr1479l04c4p65844lu8566", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"equity_research_analyst_v1\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"HUM\",\n \"currency\": \"USD\",\n \"current_price\": 198.39,\n \"target_price_6m\": 215,\n \"target_price_12m\": 231,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Revenue growth supported by aging population trends.\",\n \"Potential for margin improvement through cost efficiencies.\",\n \"Regulatory risks could limit earnings upside.\",\n \"Valuation appears reasonable relative to industry peers.\",\n \"Mixed performance with EPS decline but revenue growth.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Aging demographic demand\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Medical cost inflation\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Membership growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Technology adoption for efficiency\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive pressure\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Debt management\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Regulatory uncertainty\", \"Medical cost volatility\", \"Increased competition\", \"Economic downturn\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.025,\n \"wacc\": 0.07,\n \"terminal_multiple\": 22\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 180, \"prob\": 0.3, \"notes\": \"Earnings decline and multiple compression.\" },\n \"base\": { \"target_price\": 231, \"prob\": 0.5, \"notes\": \"Steady growth and margin improvement.\" },\n \"bull\": { \"target_price\": 260, \"prob\": 0.2, \"notes\": \"Faster growth and multiple expansion.\" }\n },\n \"method_notes\": \"DCF with earnings projection and P/E multiple. BUY due to 16% 12M upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "equity_research_analyst_v1", "risks": [ "Regulatory uncertainty", "Medical cost volatility", "Increased competition", "Economic downturn" ], "ticker": "HUM", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady growth and margin improvement.", "target_price": 231 }, "bear": { "prob": 0.3, "notes": "Earnings decline and multiple compression.", "target_price": 180 }, "bull": { "prob": 0.2, "notes": "Faster growth and multiple expansion.", "target_price": 260 } }, "confidence": 0.65, "assumptions": { "wacc": 0.07, "revenue_cagr_3y": 0.05, "terminal_multiple": 22, "ebit_margin_target": 0.025 }, "key_drivers": [ { "driver": "Aging demographic demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Medical cost inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Membership growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Technology adoption for efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Competitive pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Debt management", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF with earnings projection and P/E multiple. BUY due to 16% 12M upside. Not investment advice.", "current_price": 198.39, "recommendation": "BUY", "thesis_bullets": [ "Revenue growth supported by aging population trends.", "Potential for margin improvement through cost efficiencies.", "Regulatory risks could limit earnings upside.", "Valuation appears reasonable relative to industry peers.", "Mixed performance with EPS decline but revenue growth." ], "target_price_6m": 215, "target_price_12m": 231 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 367, "createdAt": "2026-04-09T05:21:06.247Z", "usage": { "inputTokens": 2094, "outputTokens": 2620, "costUsd": 0.001687 } }, { "id": "cmnr1479s04c7p658mkl1m3m1", "runId": "cmnr1479l04c4p65844lu8566", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst v1.0\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"HUM\",\n \"currency\": \"USD\",\n \"current_price\": 198.39,\n \"target_price_6m\": 210.00,\n \"target_price_12m\": 225.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Medicare Advantage headwinds are largely priced in at current multi-year valuation lows.\",\n \"Margin recovery expected as Humana aggressively reprices bids to reflect higher utilization trends.\",\n \"CMS rate pressures and Star Rating challenges cap near-term earnings growth potential.\",\n \"Strong balance sheet and $4.2B cash provide a buffer during the operational turnaround.\",\n \"Long-term demographic tailwinds in senior care remain intact despite current regulatory friction.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Medicare Advantage MLR\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"CMS Rate Updates\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Star Ratings Recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Cost Cutting Initiatives\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Senior Demographic Growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Value-Based Care Expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Persistent high medical utilization among seniors squeezing margins.\",\n \"Adverse regulatory changes or further CMS base rate cuts.\",\n \"Inability to quickly restore lost Star Ratings for bonus payments.\",\n \"Increased competition in the Medicare Advantage market.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.035,\n \"wacc\": 0.085,\n \"terminal_multiple\": 12.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 160.00,\n \"prob\": 0.3,\n \"notes\": \"Utilization remains elevated and CMS rates tighten further, delaying margin recovery.\"\n },\n \"base\": {\n \"target_price\": 225.00,\n \"prob\": 0.5,\n \"notes\": \"Gradual MLR stabilization and successful bid repricing lead to moderate earnings recovery.\"\n },\n \"bull\": {\n \"target_price\": 275.00,\n \"prob\": 0.2,\n \"notes\": \"Rapid Star Ratings improvement and faster-than-expected cost normalization drive multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of historical P/E reversion on normalized earnings and DCF. Target implies a 13.4% upside, supporting a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Analyst v1.0", "risks": [ "Persistent high medical utilization among seniors squeezing margins.", "Adverse regulatory changes or further CMS base rate cuts.", "Inability to quickly restore lost Star Ratings for bonus payments.", "Increased competition in the Medicare Advantage market." ], "ticker": "HUM", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual MLR stabilization and successful bid repricing lead to moderate earnings recovery.", "target_price": 225 }, "bear": { "prob": 0.3, "notes": "Utilization remains elevated and CMS rates tighten further, delaying margin recovery.", "target_price": 160 }, "bull": { "prob": 0.2, "notes": "Rapid Star Ratings improvement and faster-than-expected cost normalization drive multiple expansion.", "target_price": 275 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 12, "ebit_margin_target": 0.035 }, "key_drivers": [ { "driver": "Medicare Advantage MLR", "impact": "HIGH", "direction": "NEG" }, { "driver": "CMS Rate Updates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Star Ratings Recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost Cutting Initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Senior Demographic Growth", "impact": "MED", "direction": "POS" }, { "driver": "Value-Based Care Expansion", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a blend of historical P/E reversion on normalized earnings and DCF. Target implies a 13.4% upside, supporting a BUY rating. Not investment advice.", "current_price": 198.39, "recommendation": "BUY", "thesis_bullets": [ "Medicare Advantage headwinds are largely priced in at current multi-year valuation lows.", "Margin recovery expected as Humana aggressively reprices bids to reflect higher utilization trends.", "CMS rate pressures and Star Rating challenges cap near-term earnings growth potential.", "Strong balance sheet and $4.2B cash provide a buffer during the operational turnaround.", "Long-term demographic tailwinds in senior care remain intact despite current regulatory friction." ], "target_price_6m": 210, "target_price_12m": 225 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 21670, "createdAt": "2026-04-09T05:21:06.247Z", "usage": { "inputTokens": 2457, "outputTokens": 803, "costUsd": 0.01455 } }, { "id": "cmnr1479s04c5p658a0kcrgm1", "runId": "cmnr1479l04c4p65844lu8566", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"HUM\",\"currency\":\"USD\",\"current_price\":198.39,\"target_price_6m\":190,\"target_price_12m\":205,\"recommendation\":\"HOLD\",\"confidence\":0.58,\"thesis_bullets\":[\"Medicare Advantage scale supports long-run growth and pricing leverage.\",\"Revenue growth remains solid, but EPS is currently pressured.\",\"Current valuation looks fair on depressed earnings, not obviously cheap.\",\"Balance sheet liquidity is adequate despite meaningful debt load.\",\"Near-term reimbursement and utilization uncertainty limits rerating.\"],\"key_drivers\":[{\"driver\":\"MA reimbursement rates\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Medical cost trend\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Star ratings quality bonus\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Membership growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pricing discipline\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"CenterWell expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulatory scrutiny\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Margin recovery execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"}],\"risks\":[\"Higher-than-expected medical utilization\",\"Adverse CMS rate or risk-adjustment changes\",\"Further Medicare Advantage star-rating pressure\",\"Policy or litigation shocks\",\"Execution missteps in margin recovery\"],\"assumptions\":{\"revenue_cagr_3y\":0.07,\"ebit_margin_target\":0.028,\"wacc\":0.085,\"terminal_multiple\":14},\"scenarios\":{\"bear\":{\"target_price\":165,\"prob\":0.3,\"notes\":\"Utilization stays elevated and reimbursement fails to offset margin pressure.\"},\"base\":{\"target_price\":205,\"prob\":0.45,\"notes\":\"Margins stabilize gradually while revenue growth remains healthy.\"},\"bull\":{\"target_price\":250,\"prob\":0.25,\"notes\":\"Better pricing, star performance, and utilization normalize faster than expected.\"}},\"method_notes\":\"Targets use scenario-weighted earnings-power/multiple framework cross-checked with snapshot valuation and margins; no sell-side targets used. Snapshot quote fields kept authoritative. HOLD fits limited 12M upside versus high policy/utilization uncertainty; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Model Recommendation", "risks": [ "Higher-than-expected medical utilization", "Adverse CMS rate or risk-adjustment changes", "Further Medicare Advantage star-rating pressure", "Policy or litigation shocks", "Execution missteps in margin recovery" ], "ticker": "HUM", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Margins stabilize gradually while revenue growth remains healthy.", "target_price": 205 }, "bear": { "prob": 0.3, "notes": "Utilization stays elevated and reimbursement fails to offset margin pressure.", "target_price": 165 }, "bull": { "prob": 0.25, "notes": "Better pricing, star performance, and utilization normalize faster than expected.", "target_price": 250 } }, "confidence": 0.58, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.07, "terminal_multiple": 14, "ebit_margin_target": 0.028 }, "key_drivers": [ { "driver": "MA reimbursement rates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Medical cost trend", "impact": "HIGH", "direction": "NEG" }, { "driver": "Star ratings quality bonus", "impact": "HIGH", "direction": "POS" }, { "driver": "Membership growth", "impact": "MED", "direction": "POS" }, { "driver": "Pricing discipline", "impact": "HIGH", "direction": "POS" }, { "driver": "CenterWell expansion", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory scrutiny", "impact": "MED", "direction": "NEG" }, { "driver": "Margin recovery execution", "impact": "HIGH", "direction": "POS" } ], "method_notes": "Targets use scenario-weighted earnings-power/multiple framework cross-checked with snapshot valuation and margins; no sell-side targets used. Snapshot quote fields kept authoritative. HOLD fits limited 12M upside versus high policy/utilization uncertainty; not investment advice.", "current_price": 198.39, "recommendation": "HOLD", "thesis_bullets": [ "Medicare Advantage scale supports long-run growth and pricing leverage.", "Revenue growth remains solid, but EPS is currently pressured.", "Current valuation looks fair on depressed earnings, not obviously cheap.", "Balance sheet liquidity is adequate despite meaningful debt load.", "Near-term reimbursement and utilization uncertainty limits rerating." ], "target_price_6m": 190, "target_price_12m": 205 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_04461fbff986773a0069d759fd12348195b0b30e43b3609ea0", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 18335, "createdAt": "2026-04-09T05:21:06.247Z", "usage": { "inputTokens": 2364, "outputTokens": 996, "costUsd": 0.018081 } }, { "id": "cmnr1479s04c8p658qdcdv8bn", "runId": "cmnr1479l04c4p65844lu8566", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"HUM\",\n \"currency\": \"USD\",\n \"current_price\": 198.39,\n \"target_price_6m\": 200,\n \"target_price_12m\": 210,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.58,\n \"thesis_bullets\": [\n \"Medicare Advantage cost pressures weigh on profitability\",\n \"Solid revenue growth from membership increases continues\",\n \"Current valuation reflects tempered growth expectations\",\n \"Strong cash flow supports shareholder returns\",\n \"Policy and regulatory risks create ongoing uncertainty\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Medical cost inflation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Membership growth in MA\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"CMS reimbursement adjustments\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating expense management\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Investment income yields\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Value-based care adoption\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competitive pricing pressure\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Sustained high MLR in Medicare plans\",\n \"Negative Medicare rate updates\",\n \"Implementation risks in new initiatives\",\n \"Macroeconomic impacts on membership\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.035,\n \"wacc\": 0.09,\n \"terminal_multiple\": 12\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 165,\n \"prob\": 0.35,\n \"notes\": \"Continued high medical costs lead to further de-rating.\"\n },\n \"base\": {\n \"target_price\": 210,\n \"prob\": 0.45,\n \"notes\": \"Gradual margin stabilization aligns with current valuation.\"\n },\n \"bull\": {\n \"target_price\": 265,\n \"prob\": 0.2,\n \"notes\": \"Significant margin recovery drives multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation anchored in 8% 3Y revenue CAGR, 3.5% EBIT margin target, 9% WACC and 12x terminal multiple. Mixed MA cost trends and regulatory uncertainty support HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Analyst Model", "risks": [ "Sustained high MLR in Medicare plans", "Negative Medicare rate updates", "Implementation risks in new initiatives", "Macroeconomic impacts on membership" ], "ticker": "HUM", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Gradual margin stabilization aligns with current valuation.", "target_price": 210 }, "bear": { "prob": 0.35, "notes": "Continued high medical costs lead to further de-rating.", "target_price": 165 }, "bull": { "prob": 0.2, "notes": "Significant margin recovery drives multiple expansion.", "target_price": 265 } }, "confidence": 0.58, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.08, "terminal_multiple": 12, "ebit_margin_target": 0.035 }, "key_drivers": [ { "driver": "Medical cost inflation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Membership growth in MA", "impact": "HIGH", "direction": "POS" }, { "driver": "CMS reimbursement adjustments", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operating expense management", "impact": "MED", "direction": "POS" }, { "driver": "Investment income yields", "impact": "MED", "direction": "POS" }, { "driver": "Value-based care adoption", "impact": "MED", "direction": "POS" }, { "driver": "Competitive pricing pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation anchored in 8% 3Y revenue CAGR, 3.5% EBIT margin target, 9% WACC and 12x terminal multiple. Mixed MA cost trends and regulatory uncertainty support HOLD. Not investment advice.", "current_price": 198.39, "recommendation": "HOLD", "thesis_bullets": [ "Medicare Advantage cost pressures weigh on profitability", "Solid revenue growth from membership increases continues", "Current valuation reflects tempered growth expectations", "Strong cash flow supports shareholder returns", "Policy and regulatory risks create ongoing uncertainty" ], "target_price_6m": 200, "target_price_12m": 210 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "eed870db-b8da-9024-8d67-a02f7d9ccfae", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 24253, "createdAt": "2026-04-09T05:21:06.247Z", "usage": { "inputTokens": 2706, "outputTokens": 4010, "costUsd": 0.068268 } } ] } }